Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.

Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. Abstract Text:

Daniel J Skiest,Zhaohui Su,Diane V Havlir,Kevin R Robertson,Robert W Coombs,Pat Cain,Tianna Peterson,Amy Krambrink,Nasreen Jahed,Deborah McMahon,David M Margolis, ,

BACKGROUND: We sought to determine the safety of treatment interruption (TI) and to identify parameters that would define patients with human immunodeficiency virus (HIV) for whom TI is safer. METHODS: AIDS Clinical Trials Group 5170 was a multicenter, 96-week-long, prospective study of HIV-infected patients receiving antiretroviral therapy (ART) who had CD4(+) cell counts >350 cells/mm(3) and who underwent TI. RESULTS: A total of 167 patients were enrolled. The median nadir in CD4(+) cell count was 436 cells/mm(3). The initial decrease (i.e., during the first 8 weeks) in CD4(+) cell count after ART interruption was 20 cells/mm(3)/week; the subsequent decrease was 2.0 cells/mm(3)/week until week 96. Both the CD4(+) cell count before enrollment and the increase in CD4(+) cell count during ART predicted early decrease; later decrease was predicted by the level of interleukin-7 at enrollment. A Centers for Disease Control and Prevention (CDC) diagnosis of a category B or C event was made for 2 and 2 patients, respectively (all had CD4(+) cell counts >350 cells/mm(3)). At week 96, 17 patients had CD4(+) cell counts < or =250 cells/mm(3), and 46 patients had resumed ART; 5 patients died (unrelated to HIV or acquired immunodeficiency syndrome). In a multivariate analysis, a higher nadir in CD4(+) cell count (>400 cells/mm(3)), a lower HIV load (<50 copies/mL) at the time of TI, and an HIV load < or =22,000 copies/mL before ART predicted a longer time to the primary end point (CDC category B or C event, death, CD4(+) cell count < or =250 cells/mm(3), or resumption of ART). CONCLUSION: Disease progression after TI was low in this cohort. A higher nadir in CD4(+) cell count, a lower HIV load before ART, and an HIV load < or =50 copies/mL at the time of TI predicted a longer time to the primary end point.

Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. Publishing Authors By Initials

DJ Skiest,Z Su,DV Havlir,KR Robertson,RW Coombs,P Cain,T Peterson,A Krambrink,N Jahed,D McMahon,DM Margolis, ,

For similar investigative techniques: clinical laboratory techniques: microbiological techniques: viral load research abstracts see: investigative techniques: clinical laboratory techniques: microbiological techniques: viral load research

PUBMED ID PMID:

MEDLINE DATE:

Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: The Journal of infectious diseases

VOLUME: 195

Page Numbers: 1426-36

Journal Abbreviation:

ISSN: 0022-1899

DAY: 6

MONTH: 04

YEAR: 2007

Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 413675

Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. Keywords Mesh Terms:

KEYWORDS: Viral Load

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. Information

Substance Name: Anti-Retroviral Agents

Registry Number: 0

Grant and Affiliation Information for Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.

AFFILIATION: Baystate Medical Center, Springfield, MA 01106, USA. daniel.skiest@bhs.org

Country: United States

AGENCY: United States NIAID

GRANT: U01-AI 032783-13

ACRONYM: AI

MEDLINETA: J Infect Dis

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170 Related Publications

• "Steel wool keratopathy": a clinical sign of chronic inflammation.
• A novel Crumbs3 isoform regulates cell division and ciliogenesis via importin beta interactions.
• A novel trinucleotide repeat expansion at chromosome 3q26.2 identified by a CAG/CTG repeat expansion detection array.
• Apical junctional complexes and cell polarity.
• Bex1 knock out mice show altered skeletal muscle regeneration.
• Body dysmorphic disorder symptoms among patients with acne vulgaris.
• Confronting proviral HIV infection.
• Digital imaging of wounds: are measurements reproducible among observers?
• Effect of fluoride on artificial caries lesion progression and repair in human enamel: regulation of mineral deposition and dissolution under in vivo-like conditions.
• Emergency medical services education: past, present, and future.
• Expression of an intron-containing beta-tubulin mRNA in catfish olfactory epithelium.
• Hepatitis B vaccination of men who have sex with men attending an urban STD clinic: impact of an ongoing vaccination program, 1998-2003.
• Huntington's disease--like 2 is associated with CUG repeat-containing RNA foci.
• Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
• Mammalian lin-7 stabilizes polarity protein complexes.
• Mitosis persists in the absence of Cdk1 activity when proteolysis or protein phosphatase activity is suppressed.
• Nuclear receptors and bone.
• Obituary: arun fotedar.
• Olfactory marker protein modulates the cAMP kinetics of the odour-induced response in cilia of mouse olfactory receptor neurons.
• PALS1 regulates E-cadherin trafficking in mammalian epithelial cells.
• Radiation therapy for cutaneous squamous cell carcinoma involving the parotid area lymph nodes: dose and volume considerations.
• Repeat expansion and autosomal dominant neurodegenerative disorders: consensus and controversy.
• Restricted-carbohydrate diets in patients with type 2 diabetes: a meta-analysis.
• Sensate scaffolds coupled to telemetry can monitor in vivo loading from within a joint over extended periods of time.
• Sodium/calcium exchanger expression in the mouse and rat olfactory systems.
• Spindle cell lipoma of the mediastinum: a differential consideration for liposarcoma.
• The prevalence of atopic triad in children with physician-confirmed atopic dermatitis.
• Upper respiratory tract infection in household contacts of acne patients.
• c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter.
• pH triggered self-assembly of native and recombinant amelogenins under physiological pH and temperature in vitro.